Screening for Lung Cancer with Low-Dose CT Scans

Kansere bağlı ölüm nedenleri arasında akciğer kanseri erkeklerde birinci sırada, kadınlarda da ikinci sırada yer almaktadır. Amerika Birleşik Devletleri'nde akciğer kanseri hastalarının 5 yıllık hayatta kalma oranı %16'dır. Akciğer kanseri hastalarının sadece %15'i tanı aşamasında 1. evrededir. Hastaların %50'den daha fazlasının tanı anında IV. Evre oldukları görülmektedir. Çoğu akciğer kanseri hastasına, hastalık ileri düzeye ulaştığında kendini gösteren belirti ve semptomlar ortaya çıkana kadar tanı konulamamaktadır. Akciğer kanserinin tedavi oranının artırılması için, hasta asemptomatik iken ve kanser yayılmadan önce daha fazla sayıda vaka tespit edilmelidir. Yüksek risk altındaki bireylerde düşük-doz bilgisayarlı tomografi (DDBT) taraması, akciğer kanserinin erken evrelerde teşhis edilmesine yardımcı olabilir. ABD'de yüksek risk altındaki bireylerde DDBT taraması, standart haline gelmektedir ve akciğer kanserinden kaynaklanan ölümlerin sayısında, sigaranın bırakılması ile birlikte önemli ölçüde bir azalma sağlamaktadır. Bu makalede, DDBT ile akciğer kanseri taraması hakkında son zamanlarda yapılmış olan çalışmalar incelenmiştir.

Düşük Doz Bilgisayarlı Tomografi ile Akciğer Kanseri Taraması

Lung cancer is the leading cause of cancer deaths in males and the second leading cancer cause of death in females. The 5-year survival of all lung cancer patients in the United States is 16%. Only 15% of new lung cancers are stage I at the time of diagnosis, and over 50% of patients have stage IV lung cancer at diagnosis. Most lung cancers are not diagnosed until the patient presents with signs or symptoms of disease, and these are usually due to advanced-stage disease. If we are going to increase the cure rate for lung cancer, then more cases must be detected while the patient is asymptomatic and before the cancer has spread. Screening of high-risk individuals with low-dose computed tomography (LDCT) may help in diagnosing the lung cancer at earlier stages. Screening with LDCT in high-risk individuals is becoming the standard of care in the United States and, along with smoking cessations, offers the best opportunity for decreasing a substantial number of lung cancer deaths. In this article, recent manuscripts about lung cancer screening with LDCT have been reviewed

Kaynakça

IARC WHO. Globocan 2012. http://globocan.iarc.fr.

Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29. [CrossRef]

National Lung Screening Trial Research T, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, et al. Reduced lung-cancer mortality with low-dose com- puted tomographic screening. N Eng J Med 2011; 365: 395-409. [CrossRef]

National Lung Screening Trial Research T, Church TR, Black WC, Aberle DR, Berg CD, Clingan KL, et al. Results of initial low-dose computed to- mographic screening for lung cancer. N Eng J Med 2013; 368: 1980-91. [CrossRef]

Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, et al. Re- sults of the two incidence screenings in the national lung screening trial. N Eng J Med 2013; 369: 920-31. [CrossRef]

Veronesi G, Maisonneuve P, Bellomi M, Rampinelli C, Durli I, Bertolotti R, et al. Estimating overdiagnosis in low-dose computed tomography screening for lung cancer: a cohort study. Ann Itern Med 2012; 157: 776-84. [CrossRef]

Patz EF, Jr., Pinsky P, Gatsonis C, Sicks JD, Kramer BS, Tammemagi MC, et al. Overdiagnosis in low-dose computed tomography screening for lung cancer. JAMA Intern Med 2014; 174: 269-74. [CrossRef]

de Koning HJ, Meza R, Plevritis SK, ten Haaf K, Munshi VN, Jeon J, et al. Benefits and harms of computed tomography lung cancer screening strategies: A comparative modeling study for the U.S. Preventive services task force. Ann Intern Med 2014; 160: 311-20. [CrossRef]

Pinsky PF, Berg CD. Applying the national lung screening trial eligibility crite- ria to the us population: What percent of the population and of incident lung cancers would be covered? J Med Screen 2012; 19: 154-56. [CrossRef]

Ma J, Ward EM, Smith R, Jemal A. Annual number of lung cancer deaths potentially avertable by screening in the United States. Cancer 2013; 119: 1381-5. [CrossRef]

Moyer VA. Screening for lung cancer: U.S. Preventive services task force recommendation statement. Annals of internal medicine 2014; 160: 330-8. [CrossRef]

Wisnivesky JP, Mushlin AI, Sicherman N, Henschke C. The cost-effec- tiveness of low-dose ct screening for lung cancer: Preliminary results of baseline screening. Chest 2003; 124: 614-21. [CrossRef]

McMahon PM, Kong CY, Bouzan C, Weinstein MC, Cipriano LE, Tramontano AC, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol 2011; 6: 1841-8. [CrossRef]

Mahadevia PJ, Fleisher LA, Frick KD, Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smok- ers: a decision and cost-effectiveness analysis. JAMA 2003; 289: 313-22. [CrossRef]

Berg C. Cost effectiveness of ct screening. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013; 8: 96.

Weinstein MC, Skinner JA. Comparative effectiveness and health care spending - implications for reform. N England J Med 2010; 362: 460-5. [CrossRef]

van der Aalst CM, van den Bergh KA, Willemsen MC, de Koning HJ, van Klaveren RJ. Lung cancer screening and smoking abstinence: 2 year fol- low-up data from the dutch-belgian randomised controlled lung cancer screening trial. Thorax 2010; 65: 600-5. [CrossRef]

Villanti AC, Jiang Y, Abrams DB, Pyenson BS. A cost-utility analysis of lung cancer screening and the additional benefits of incorporating smoking cessation interventions. PloS one 2013; 8: e71379. [CrossRef]

Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lung-can- cer death. N Eng J Med 2013; 369: 245-54. [CrossRef]

Tammemagi MC, Katki HA, Hocking WG, Church TR, Caporaso N, Kvale PA, et al. Selection criteria for lung-cancer screening. N Eng J Med 2013; 368: 728-36. [CrossRef]

van Iersel CA, de Koning HJ, Draisma G, Mali WP, Scholten ET, Nackaerts K, et al. Risk-based selection from the general population in a screening trial: Selection criteria, recruitment and power for the dutch-belgian ran- domised lung cancer multi-slice ct screening trial (nelson). Int J Cancer 2007; 120: 868-74. [CrossRef]

Roberts H, Walker-Dilks C, Sivjee K, Ung Y, Yasufuku K, Hey A, et al. Screen- ing high-risk populations for lung cancer: Guideline recommendations. J Thorac Oncol 2013; 8: 1232-7. [CrossRef]

CDC. Best practices for comprehensive tobacco control programs. Avail- able at http://wwwcdcgov/tobacco/stateand community/best_practic- es/indexhtm 2007;US Department of Health and Human Services.

Holford TR, Meza R, Warner KE, Meernik C, Jeon J, Moolgavkar SH, et al. Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012. JAMA 2014; 311: 164-71. [CrossRef]

Kaynak Göster

Solunum
  • ISSN: 1302-4922
  • Yayın Aralığı: Yılda 0 Sayı
  • Başlangıç: 2018

34976